Pfizer's Trump Rx deal lifts policy overhang
The guest argued that the Trump administration's 'Trump Rx' pricing deal with Pfizer removes a significant policy uncertainty overhang that had been weighing on pharmaceutical stocks.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.